Publications by authors named "T Chisesi"

Background: Cancer incidence in the Galapagos archipelago is unknown.

Aim: In 2021, a task force including Ecuadorian and Italian researchers was established to estimate cancer incidence among the 25 244 Galapagos residents.

Methods: Registration covered all malignancies, including malignant melanoma and non-melanoma skin cancers; case recording was based on the International Classification of Diseases for Oncology.

View Article and Find Full Text PDF

Purpose: The Intergruppo Italiano Linfomi HD9601 trial compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus doxorubicin, vinblastine, mechloretamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V [StV]) versus the combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) with epidoxorubicin, bleomycin, vinblastine (EBV), lomustine, doxorubicin, and vindesine (CAD) (MOPP/EBV/CAD [MEC]) for the initial treatment of advanced-stage Hodgkin's lymphoma to select which regimen would best support a reduced radiotherapy program (limited to two or fewer sites of either previous bulky or partially remitting disease). Superiority of ABVD and MEC to StV was demonstrated. We report analysis of long-term outcome and toxicity.

View Article and Find Full Text PDF
Article Synopsis
  • *First-line therapy for non-MALT primary lung non-Hodgkin's lymphomas is anthracycline-based chemotherapy, with second-line therapy involving high-dose chemotherapy and autologous stem cell transplantation.
  • *For primary mediastinal large B-cell lymphomas, treatment combines chemotherapy and radiotherapy, with rituximab suggested only in clinical trials, particularly for patients showing inadequate early responses.
View Article and Find Full Text PDF

In this prospective multicentric study, we investigated the contribution of positron emission tomography (PET) scanning to the staging of Hodgkin's lymphoma (HL) by computed tomography (CT) and attempted to determine whether it has any impact on therapeutic approach. One hundred eighty six consecutive patients with HL from six Italian centers were enrolled in this study. They were staged with conventional methods; 2-[fluorine-18]fluoro-2-deoxy-D: -glucose PET scanning were prospectively compared to CT.

View Article and Find Full Text PDF

B-CLL patients with resistant/relapsed disease or adverse prognostic factors at presentation are suitable for alternative treatments. In the present pilot study we investigated a novel intensive chemo-immunotherapy approach for high-risk, fludarabine pretreated patients. Ten patients with resistant/relapsed, advanced stage BCLL were included.

View Article and Find Full Text PDF